BRISTOL-MYERS SQUIBB COMPANY Tax Adjustments, Settlements, and Unusual Provisions
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Tax Adjustments, Settlements, and Unusual Provisions of $56.00 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-02-25.
Discontinued › Notes › Income Taxes
us-gaap:TaxAdjustmentsSettlementsAndUnusualProvisions · last filed 2019-02-25
- BRISTOL-MYERS SQUIBB COMPANY tax adjustments, settlements, and unusual provisions for the quarter ending 2018-12-31 was $105.00M.
- BRISTOL-MYERS SQUIBB COMPANY tax adjustments, settlements, and unusual provisions for the quarter ending 2018-09-30 was -$20.00M.
- BRISTOL-MYERS SQUIBB COMPANY tax adjustments, settlements, and unusual provisions for the quarter ending 2018-06-30 was -$61.00M.
- BRISTOL-MYERS SQUIBB COMPANY tax adjustments, settlements, and unusual provisions for the quarter ending 2018-03-31 was $32.00M.
- BRISTOL-MYERS SQUIBB COMPANY tax adjustments, settlements, and unusual provisions for fiscal 2018 was $56.00M.
| Period end | Tax Adjustments, Settlements, and Unusual Provisions 3 month | Tax Adjustments, Settlements, and Unusual Provisions 6 month | Tax Adjustments, Settlements, and Unusual Provisions 9 month | Tax Adjustments, Settlements, and Unusual Provisions 12 month |
|---|---|---|---|---|
| 2018-12-31 | $105.00M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-25 | $85.00M derived: sum of 2 quarters · filed 2019-02-25 | $24.00M derived: sum of 3 quarters · filed 2019-02-25 | $56.00M 10-K · filed 2019-02-25 |
| 2018-09-30 | -$20.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-25 | -$81.00M derived: sum of 2 quarters · filed 2018-10-25 | -$49.00M 10-Q · filed 2018-10-25 | |
| 2018-06-30 | -$61.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-07-26 | -$29.00M 10-Q · filed 2018-07-26 | ||
| 2018-03-31 | $32.00M 10-Q · filed 2018-04-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |